Biogennix announced that its DirectCell Advanced Bone Grafting System has been used in more than 1,000 cases as of this quarter, up from 500 cases as reported in 2Q22.
DirectCell includes an advanced synthetic bone graft material with properties designed to enhance cellular bone formation, along with novel instrumentation engineered to harvest high concentrations of patient stem cells.
The bone graft within the system is Biogennix’s premium product, Agilon, which is available in a Moldable and Strip form. Agilon products are based on Biogennix’s TrelCor technology that contains a nanocrystalline hydroxycarbanoapatite graft surface to actively promote bone regeneration.
DirectCell provides surgeons with two methods of collecting bone marrow-derived stem cells, either through the harvesting of stem cell aspirate or marrow-rich autograft dowels. Together, the technologies within the DirectCell System allow surgeons to leverage both synthetic material technology and a patient’s own stem cells.
Biogennix announced that its DirectCell Advanced Bone Grafting System has been used in more than 1,000 cases as of this quarter, up from 500 cases as reported in 2Q22.
DirectCell includes an advanced synthetic bone graft material with properties designed to enhance cellular bone formation, along with novel instrumentation engineered to...
Biogennix announced that its DirectCell Advanced Bone Grafting System has been used in more than 1,000 cases as of this quarter, up from 500 cases as reported in 2Q22.
DirectCell includes an advanced synthetic bone graft material with properties designed to enhance cellular bone formation, along with novel instrumentation engineered to harvest high concentrations of patient stem cells.
The bone graft within the system is Biogennix’s premium product, Agilon, which is available in a Moldable and Strip form. Agilon products are based on Biogennix’s TrelCor technology that contains a nanocrystalline hydroxycarbanoapatite graft surface to actively promote bone regeneration.
DirectCell provides surgeons with two methods of collecting bone marrow-derived stem cells, either through the harvesting of stem cell aspirate or marrow-rich autograft dowels. Together, the technologies within the DirectCell System allow surgeons to leverage both synthetic material technology and a patient’s own stem cells.
Copy to clipboard 
